<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2015-12-03" updated="2019-12-02">
  <drugbank-id primary="true">DB11330</drugbank-id>
  <drugbank-id>DB09058</drugbank-id>
  <drugbank-id>DB14047</drugbank-id>
  <name>Factor IX Complex (Human)</name>
  <description>Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (Stuart-Prower Factor), and low levels of Factor VII (proconvertin) derived from human plasma.  Many commercially available products also contain low levels of other antithrombotic proteins. For example, Kcentra (FDA) also contains the antithrombotic proteins C and S, while Bebulin VH (FDA) contains heparin. Coagulation factors are purified from pooled human plasma and subsequently sterilized and treated. &#13;
&#13;
Although Factor IX Complex products contain many different coagulation components, Factor IX  is the lead component for potency and efficacy, particularly when used for the treatment of bleeding associated with Hemophilia B (Factor IX deficiency).  As the product Kcentra, Factor IX Complex is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients experiencing acute major bleeding or requiring rapid reversal of therapy.</description>
  <cas-number>37224-63-8</cas-number>
  <unii>FW411QXD5M</unii>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A18548</ref-id>
        <pubmed-id>26685667</pubmed-id>
        <citation>Hedges A, Coons JC, Saul M, Smith RE: Clinical effectiveness and safety outcomes associated with prothrombin complex concentrates. J Thromb Thrombolysis. 2016 Jul;42(1):6-10. doi: 10.1007/s11239-015-1321-4.</citation>
      </article>
      <article>
        <ref-id>A18549</ref-id>
        <pubmed-id>27546767</pubmed-id>
        <citation>Sin JH, Berger K, Lesch CA: Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation. J Crit Care. 2016 Jul 5;36:166-172. doi: 10.1016/j.jcrc.2016.06.024.</citation>
      </article>
      <article>
        <ref-id>A18550</ref-id>
        <pubmed-id>27488143</pubmed-id>
        <citation>Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, Crowther M: Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost. 2016 Aug 4;116(4).</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Factor IX Complex is indicated for the prevention and control of hemorrhagic episodes in hemophilia B patients. It is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or who require rapid reversal of therapy. </indication>
  <pharmacodynamics/>
  <mechanism-of-action>Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (Stuart-Prower Factor), and low levels of Factor VII (proconvertin) derived from human plasma.  Many commercially available products also contain low levels of other antithrombotic proteins. For example, Kcentra(FDA) also contains the antithrombotic proteins C and S, while Bebulin VH (FDA) contains heparin.&#13;
&#13;
This complex of coagulation factors helps replenish clotting factors that may have been lost through warfarin therapy or through a congenital abnormality such as Hemophilia B. </mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">4F-PCC</synonym>
    <synonym language="english" coder="">APCC</synonym>
    <synonym language="english" coder="">Coagulation factor IX complex human</synonym>
    <synonym language="english" coder="">Coagulation factor IX, II, VII and X in combination</synonym>
    <synonym language="english" coder="">Factor IX Complex</synonym>
    <synonym language="english" coder="">Factor IX Complex (Human)</synonym>
    <synonym language="english" coder="">Factor IX complex human</synonym>
    <synonym language="english" coder="">Factor IX complex,human</synonym>
    <synonym language="english" coder="">Factor IX Fraction</synonym>
    <synonym language="english" coder="">PCC</synonym>
    <synonym language="english" coder="">Plasma Concentrate Factor IX</synonym>
    <synonym language="english" coder="">Prothrombin complex concentrate</synonym>
    <synonym language="english" coder="">Prothrombin complex concentrate (human)</synonym>
  </synonyms>
  <products>
    <product>
      <name>Alphanine Pws Inj 1500unit/vial</name>
      <labeller>Alpha Therapeutic Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01924745</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2001-07-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bebulin Vh 500unit/vial</name>
      <labeller>Osterreichisches Institut Fur Haemoderivate Ges M.B.H.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00781347</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-13</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bebulin Vh Inj 1000unit/vial</name>
      <labeller>Osterreichisches Institut Fur Haemoderivate Ges M.B.H.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01992910</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-13</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Feiba Vh Immuno Anti Inhibitor</name>
      <labeller>Osterreichisches Institut Fur Haemoderivate Ges M.B.H.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00609137</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-13</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Profilnine</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68516-3201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>500 [iU]/5mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA102476</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Profilnine</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68516-3207</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>500 [iU]/5mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA102476</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Profilnine</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68516-3202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA102476</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Profilnine</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68516-3208</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA102476</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Profilnine</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68516-3203</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>150 [iU]/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA102476</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Profilnine</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68516-3209</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>150 [iU]/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA102476</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Profilnine</name>
      <ingredients>Factor IX Complex (Human)</ingredients>
    </mixture>
    <mixture>
      <name>Profilnine</name>
      <ingredients>Factor IX Complex (Human)</ingredients>
    </mixture>
    <mixture>
      <name>Profilnine</name>
      <ingredients>Factor IX Complex (Human)</ingredients>
    </mixture>
    <mixture>
      <name>Profilnine</name>
      <ingredients>Factor IX Complex (Human)</ingredients>
    </mixture>
    <mixture>
      <name>Profilnine</name>
      <ingredients>Factor IX Complex (Human)</ingredients>
    </mixture>
    <mixture>
      <name>Profilnine</name>
      <ingredients>Factor IX Complex (Human)</ingredients>
    </mixture>
    <mixture>
      <name>Alphanine Pws Inj 1500unit/vial</name>
      <ingredients>Factor IX Complex (Human)</ingredients>
    </mixture>
    <mixture>
      <name>Bebulin Vh Inj 1000unit/vial</name>
      <ingredients>Factor IX Complex (Human) + Water</ingredients>
    </mixture>
    <mixture>
      <name>Feiba Vh Immuno Anti Inhibitor</name>
      <ingredients>Antihemophilic factor human + Coagulation factor VII human + Coagulation factor X human + Factor IX Complex (Human) + Prothrombin</ingredients>
    </mixture>
    <mixture>
      <name>Bebulin Vh 500unit/vial</name>
      <ingredients>Factor IX Complex (Human)</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood Coagulation Factors</category>
      <mesh-id>D001779</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Enzyme Precursors</category>
      <mesh-id>D004792</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Factor IX</category>
      <mesh-id>D005164</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength>100 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength>150 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength>500 [iU]/5mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB11330.pdf?1472573645</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00513</drugbank-id>
      <name>Aminocaproic acid</name>
      <description>The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Factor IX Complex (Human).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13923</drugbank-id>
      <name>Emicizumab</name>
      <description>The risk or severity of hypercoagulability can be increased when Emicizumab is combined with Factor IX Complex (Human).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00058</drugbank-id>
      <name>Alpha-1-proteinase inhibitor</name>
      <description>Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor IX Complex (Human).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00170</drugbank-id>
      <name>Menadione</name>
      <description>Menadione may increase the thrombogenic activities of Factor IX Complex (Human).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00302</drugbank-id>
      <name>Tranexamic acid</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Factor IX Complex (Human).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>Aprotinin may increase the thrombogenic activities of Factor IX Complex (Human).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11091</drugbank-id>
      <name>Hydrogen peroxide</name>
      <description>Hydrogen peroxide may increase the thrombogenic activities of Factor IX Complex (Human).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13244</drugbank-id>
      <name>Aminomethylbenzoic acid</name>
      <description>Aminomethylbenzoic acid may increase the thrombogenic activities of Factor IX Complex (Human).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13729</drugbank-id>
      <name>Camostat</name>
      <description>Camostat may increase the thrombogenic activities of Factor IX Complex (Human).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12726</drugbank-id>
      <name>Monteplase</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Monteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Drotrecogin alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Streptokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan polysulfate</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Pentosan polysulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Epoprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Desmoteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Defibrotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Beraprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Fibrinolysin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Prasugrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Cangrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Astaxanthin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Apixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Amediplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Tinzaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Ferulic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Triflusal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Ticagrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Ditazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Vorapaxar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Edoxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Potassium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Bemiparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Parnaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11154</drugbank-id>
      <name>Zinc citrate</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Zinc citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11166</drugbank-id>
      <name>Antithrombin Alfa</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Antithrombin Alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11984</drugbank-id>
      <name>Letaxaban</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Letaxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Darexaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Betrixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Brinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13616</drugbank-id>
      <name>Melagatran</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Melagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Saruplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Tocopherylquinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14598</drugbank-id>
      <name>Edetate calcium disodium anhydrous</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Edetate calcium disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14600</drugbank-id>
      <name>Edetate disodium anhydrous</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Edetate disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14726</drugbank-id>
      <name>Dabigatran</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Dabigatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06294</drugbank-id>
      <name>Semuloparin</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Semuloparin.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>4230</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347911188</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Prothrombin_complex_concentrate</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2109098</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/profilnine-drug.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>https://www.drugs.com/monograph/factor-ix-human-factor-ix-complex-human.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>